Our study supports the clinical attractiveness of using SPP86 in the treatment of patients with RET-positive MTC, considering the relevant anti-tumor activity of this molecule modulated by stimulation of apoptosis/necrosis and inhibition of migration and tumor-induced angiogenesis. The gene discussed is RET; the disease is neoplasm.